PIPERACILLIN SODIUM; TAZOBACTAM SODIUM | A203720 | FRESENIUS KABI ANTI INFECTIVES SRL
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen petition from Qilu Pharmaceutical Co., Ltd FDA-2020-P-1356 · 3 docket documents Qilu Pharma, Inc., the US agent for Qilu Pharmaceutical Co., Ltd., filed this petition on May 7, 2020, requesting that the FDA designate a second reference listed drug (RLD) for Piperacillin and Tazobactam for Injection (EQ 36 GM BASE/VIAL; EQ 4.5 GM BASE/VIAL) because the current RLD, Zosyn, is in | Other | 2020-05-08 | Withdrawn | Qilu Pharmaceutical Co., Ltd |
Source: Regulations.gov. FDA citizen petitions matched by application number.
No patent or exclusivity listings for this strength.